Hypofractionated Radiotherapy vs. Single Fraction Radiosurgery for Brain Metastasis Patients on immunotherapy (HYPOGRYPHE)
Protocol: WF-2201 SCHEMA WF-2201 Please Note: Below is a brief list of eligibility, please contact the Genesys Hurley Cancer Institute, Research Department at (810)762-8181, (810)762-8079 or (810)762-8038, to discuss the full list of eligibility. Eligibility: At least one intact brain metastasis or resection cavity ≥ 2 cm in diameter or ≥ 4 cc volume with […]
Phase II Trial of SMO/AKT/NF2/CDK Inhibitors in Progressive Meningiomas with SMO/AKT/NF2/CDK Pathway Mutations
Protocol – Alliance A071401 Please Note: Below is partial eligibility, please contact GHCI Research Department at (810)762-8181, (810)762-8079 or (810)762-8038 for full eligibility requirements. Thank you! SCHEMA A071401 Eligibility: Pre-Registration: Local diagnosis of meningioma and have tissue available for central path review and integral biomarker testing. Registration Eligibility: Presence of specific SMO/PTCH1, NF2 or AKT1/PIK3CA./CDK […]
Genomically Guided Treatment Trial in Brain Metastases
Protocol – Alliance – A071701 SCHEMA A071701 Please Note: Below is partial eligibility, please contact GHCI Research Department for full eligibility requirements at (810) 762-8181, (810) 762-8079 and/or (810) 762-8038. Thank you! Pre-Eligibility: Tissue available for biomarker testing (any brain metastasis tissue and extracranial site from any prior resection or biopsy). If the patient does […]